Harmony Biosciences Inc. (HRMY)
NASDAQ: HRMY
· Real-Time Price · USD
27.23
0.19 (0.70%)
At close: Sep 26, 2025, 11:05 AM
0.70% (1D)
| Bid | 19.57 |
| Market Cap | 1.57B |
| Revenue (ttm) | 772.53M |
| Net Income (ttm) | 180.9M |
| EPS (ttm) | 3.1 |
| PE Ratio (ttm) | 8.78 |
| Forward PE | 6.88 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 34.43 |
| Volume | 189,097 |
| Avg. Volume (20D) | 724,065 |
| Open | 27.11 |
| Previous Close | 27.04 |
| Day's Range | 26.72 - 27.30 |
| 52-Week Range | 26.35 - 41.61 |
| Beta | 0.84 |
| Ex-Dividend Date | n/a |
About HRMY
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol HRMY
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for HRMY stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsHarmony Biosciences Inc. is scheduled to release its earnings on
Oct 28, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 days ago
-16.56%
Harmony Biosciences Holdings shares are trading lo...
Unlock content with
Pro Subscription
2 weeks ago
-5.11%
Harmony Biosciences shares are trading lower. Needham lowered its price target on the stock from $49 to $48.
1 month ago · seekingalpha.com
Harmony Biosciences Holdings, Inc. (HRMY) Q2 2025 Earnings Call TranscriptHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY ) Q2 2025 Earnings Conference Call August 5, 2025 8:30 AM ET Company Participants Adam Zaeske - Executive VP & Chief Commercial Officer Brennan Doyle - ...
